

RECEIVED  
CENTRAL FAX CENTER

Tanox, Inc. DEC 27 2004



10301 Stella Link  
Houston, TX 77025  
(713) 578-4000  
FAX 713-578-5005

FAX TRANSMISSION COVER SHEET

Date: December 27, 2004  
To: Dr. Lorraine Spector  
Company: United States Patent & Trademark Office  
Fax: (703) 872-9306  
Sender: Cheryl A. Liljestrand  
RE: Response to Restriction Requirement

You should receive 3 page(s), including this cover.  
If you do not receive all pages, please call (713) 578-4182.

Certificate of Transmission

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (703)872-9306, on December 27, 2004

Typed or printed name of person signing this certificate:

Cheryl A. Liljestrand

Signature: Cheryl A. Liljestrand

RECEIVED  
CENTRAL FAX CENTER

DEC 27 2004

PATENT  
ATTORNEY DOCKET NO.: TNX98-03-01  
CUSTOMER NO: 26839

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:  
Ni, Baofu et al.

Serial No.: 10/071,962

Filed: February 8, 2002

For: G-CSF RECEPTOR AGONIST  
ANTIBODIES AND SCREENING  
METHODS THEREFOR

Group Art Unit: 1647

Examiner: L. Spector

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

## RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement dated September 24, 2004, Applicants submit the following election. The period for response has been extended to December 24, 2004, by a Request for a two-month extension of time. Please charge our deposit account No. 20-0087.

Applicants elect Group I, Claims 31-45, drawn to agonist antibodies. Applicants further elect the species, Mab 163-93. The sequences corresponding to this antibody comprise SEQ ID NOs: 15-20 as indicated on page 27 of the specification.

Light chain sequences are as follows:

CDR-L1 – SEQ ID NO: 15; CDR-L2 – SEQ ID NO: 16; CDR-L3 – SEQ ID NO: 17;

Heavy chain sequences are as follows:


CDR-H1 – SEQ ID NO:18; CDR-H2 – SEQ ID NO:19; CDR-H3 – SEQ ID NO:20.

Applicants reserve the right to rejoin claims 46-47, upon a finding that the product claims are allowable.

Respectfully Submitted

Dated: December 27, 2004

BY:

  
Cheryl A. Liljestrand  
Reg. No. 45,275